As COVID Vaccines Fast Approach for Adults, Researchers Prepare for Large-Scale Growth in Pediatrics

Share Article

Pediatric vaccine development has been one of the fastest growing areas in clinical research prior to the COVID-19 pandemic. Platinum Research Network has been actively supporting Phase I-III COVID-19 vaccine trials in adults and is fully prepared for upcoming trials in pediatric age groups. These trials are necessary to efficiently bring life-changing vaccines to the market.

Platinum Research Network

Kip McKenzie, President of Tekton Research, states, “Through the strength and collaborative relationships with Sponsors and CRO’s and extensive experience with enrollment of pediatric studies, we are prepared to successfully enroll pediatric COVID-19 trials.”

It’s clear that parents hope to send their kids back to school safely and continue with normal activities. The FDA states, “Vaccines that are being developed for children are first tested in adults.” With a vaccine available to adults and children, a return to normalcy could be in the near future.

Pediatric vaccine development has been one of the fastest growing areas in clinical research prior to the COVID-19 pandemic. Platinum Research Network (PRN) represents six companies who are at the forefront of pediatric vaccine research. One of the companies represented by PRN, Tekton Research, has had one of the most steadfast and comprehensive strategies for meeting client needs in pediatric clinical research trials and presents with a clear solution to pediatric COVID-19 vaccine trials. Kip McKenzie, President of Tekton Research, states, “Through the strength and collaborative relationships with Sponsors and CRO’s and extensive experience with enrollment of pediatric studies, we are prepared to successfully enroll pediatric COVID-19 trials.”

PRN’s members have responded to the requirement of ensuring inclusion of a diverse population of subjects in clinical trials by expanding research operations into new markets, with a growth rate averaging at 60%. To date, PRN investigators have conducted hundreds of pediatric vaccine studies and have enrolled thousands of pediatric patients into clinical trials over the last 20 years. Jason Roth, VP of Business Development of PRN, states, “The unmatched experience in pediatric vaccine trials puts PRN in a unique position to fully support clinical trials for Sponsors and CRO’s, including upcoming COVID-19 vaccine trials in pediatrics. Research must continue forward, especially in response to this pandemic. The health of our children’s children depends on it.”

Mr. Roth continues, “Tekton Research is one of the fastest growing companies in our network, and like all PRN companies, Tekton’s growth has been strategic.” During the pandemic, PRN companies have grown their teams across multiple departments including quality assurance, training, and patient recruitment, and continue to maintain excellent retention of subjects. “Their performance metrics speak for themselves and compliment their current efforts.” Roth added.

Platinum Research Network has been actively supporting Phase I-III COVID-19 vaccine trials in adults and is fully prepared for upcoming trials in pediatric age groups. These trials are necessary to efficiently bring life-changing vaccines to the market. The CDC states, “On-time vaccination throughout childhood is essential, because it helps provide immunity before children are exposed to potentially life-threatening diseases. Vaccines are tested to ensure that they are safe and effective for children to receive at the recommended ages.”

Jason Roth, Principal Investigators, and other PRN members are available for interview via phone or various other online platforms. Please reach out if you have any inquiries about Platinum Research Network’s capabilities, or if you are interested in collaborating.

https://www.fda.gov/files/vaccines,%20blood%20&%20biologics/published/Ensuring-the-Safety-of-Vaccines-in-the-United-States.pdf

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Lauren Foreman

Jason Roth
Visit website